secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001213900-23-022428
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Q4 net loss $37.9M; cash at $148.3M; plans revised REL-1017 MDD trials after Study 301 failure
--------------------------------------------------------------------------------

- Q4 2022 net loss $37.9M ($1.28/diluted share), vs $34.4M ($1.80) in Q4 2021; full-year net loss $157.0M.
- Cash and short-term investments $148.3M at Dec 31, 2022, down from $211.9M a year earlier.
- Will amend ongoing Phase 3 Study 302 and initiate new Study 304 for REL-1017 as adjunctive MDD treatment.
- Appointed Cedric O'Gorman, M.D. as CMO and Fabiana Fedeli as independent board director.
- Study 302 enrollment expected H1 2024; Study 304 to start mid-2023 with data in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023022428/0001213900-23-022428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023022428/ea175642-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-022428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer